$GOVX
GeoVax Labs, Inc.

2017 Form 10-K Financial Statement

#000143774918005301 Filed on March 23, 2018

View on sec.gov

Income Statement

Concept 2017 2016 Q4 2016
Revenue $1.075M $170.0K $828.9K
YoY Change 29.72% 6.21% 93.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.230M $660.0K $2.130M
YoY Change -42.25% 100.0% 48.95%
% of Gross Profit
Research & Development $2.017M $450.0K $1.971M
YoY Change 2.36% -15.09% 16.41%
% of Gross Profit
Depreciation & Amortization $28.03K $10.00K $28.78K
YoY Change -2.62% 0.0% -0.54%
% of Gross Profit
Operating Expenses $3.250M $1.110M $4.102M
YoY Change -20.78% 30.59% 31.36%
Operating Profit -$2.174M -$3.273M
YoY Change -33.57% 21.47%
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $4.286K $1.666K
YoY Change 157.26% -69.52%
Pretax Income -$2.170M -$940.0K -$3.270M
YoY Change -33.64% 36.23% 21.56%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.170M -$940.0K -$3.272M
YoY Change -33.67% 35.69% 21.66%
Net Earnings / Revenue -201.82% -552.94% -394.7%
Basic Earnings Per Share
Diluted Earnings Per Share -$632.6B -$376.6B -$1576B
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $310.0K $450.0K $450.0K
YoY Change -31.11% -57.55% -57.55%
Cash & Equivalents $310.0K $454.0K $450.0K
Short-Term Investments
Other Short-Term Assets $80.00K $60.00K $60.00K
YoY Change 33.33% 0.0% 0.0%
Inventory
Prepaid Expenses
Receivables $60.00K $30.00K $30.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $450.0K $544.4K $540.0K
YoY Change -16.67% -55.99% -56.45%
LONG-TERM ASSETS
Property, Plant & Equipment $30.00K $54.83K $50.00K
YoY Change -40.0% -34.42% -37.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $11.01K $10.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $40.00K $65.84K $70.00K
YoY Change -42.86% -30.42% -22.22%
TOTAL ASSETS
Total Short-Term Assets $450.0K $544.4K $540.0K
Total Long-Term Assets $40.00K $65.84K $70.00K
Total Assets $490.0K $610.2K $610.0K
YoY Change -19.67% -54.17% -54.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $80.00K $75.61K $80.00K
YoY Change 0.0% -25.09% -20.0%
Accrued Expenses $730.0K $294.2K $290.0K
YoY Change 151.72% 1029.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $810.0K $369.8K $370.0K
YoY Change 118.92% 191.24% 184.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $810.0K $369.8K $370.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $810.0K $370.0K $370.0K
YoY Change 118.92% 184.62% 184.62%
SHAREHOLDERS EQUITY
Retained Earnings -$35.75M
YoY Change 10.07%
Common Stock $34.97M
YoY Change 7.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$320.0K $240.4K $240.0K
YoY Change
Total Liabilities & Shareholders Equity $490.0K $610.2K $610.0K
YoY Change -19.67% -54.17% -54.14%

Cashflow Statement

Concept 2017 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$2.170M -$940.0K -$3.272M
YoY Change -33.67% 35.69% 21.66%
Depreciation, Depletion And Amortization $28.03K $10.00K $28.78K
YoY Change -2.62% 0.0% -0.54%
Cash From Operating Activities -$1.688M -$370.0K -$1.946M
YoY Change -13.24% -51.95% -28.06%
INVESTING ACTIVITIES
Capital Expenditures $4.350K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.350K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $571.5K $1.340M
YoY Change -57.34%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.552M 310.0K 1.340M
YoY Change 15.8% -50.0%
NET CHANGE
Cash From Operating Activities -1.688M -370.0K -1.946M
Cash From Investing Activities -4.350K 0.000
Cash From Financing Activities 1.552M 310.0K 1.340M
Net Change In Cash -141.3K -60.00K -606.3K
YoY Change -76.69% -92.21% 1367.98%
FREE CASH FLOW
Cash From Operating Activities -$1.688M -$370.0K -$1.946M
Capital Expenditures $4.350K $0.00
Free Cash Flow -$1.693M -$370.0K -$1.946M
YoY Change -13.02% -51.95% -28.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 govx Accrued Directors Fees Current
AccruedDirectorsFeesCurrent
182620
CY2016Q4 govx Accrued Directors Fees Current
AccruedDirectorsFeesCurrent
78070
CY2017 govx Class Of Warrant Or Right Exchanged During Period Exercise Price
ClassOfWarrantOrRightExchangedDuringPeriodExercisePrice
0.02
CY2017 govx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
31639577
CY2017 govx Class Of Warrant Or Right Forfeited Or Expired During Period
ClassOfWarrantOrRightForfeitedOrExpiredDuringPeriod
1112001
CY2017 govx Class Of Warrant Or Right Forfeited Or Expired During Period Exercise Price
ClassOfWarrantOrRightForfeitedOrExpiredDuringPeriodExercisePrice
0.57
CY2017 govx Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
CY2017 govx Class Of Warrant Or Right Issued During Period Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
CY2017Q4 govx Deferred Tax Assets Accrued Salaries And Directors Fees
DeferredTaxAssetsAccruedSalariesAndDirectorsFees
185961
CY2016Q4 govx Deferred Tax Assets Accrued Salaries And Directors Fees
DeferredTaxAssetsAccruedSalariesAndDirectorsFees
CY2017Q4 govx Deferred Tax Assets Before Valuation Allowance Net
DeferredTaxAssetsBeforeValuationAllowanceNet
19123959
CY2016Q4 govx Deferred Tax Assets Before Valuation Allowance Net
DeferredTaxAssetsBeforeValuationAllowanceNet
28331759
CY2017 govx Deferred Tax Assets From Remeasurement Due To Changes In Enacted Tax Rate
DeferredTaxAssetsFromRemeasurementDueToChangesInEnactedTaxRate
-10100000
CY2016Q4 us-gaap Assets
Assets
610217
CY2017Q4 us-gaap Assets Current
AssetsCurrent
448074
CY2016Q4 us-gaap Assets Current
AssetsCurrent
544379
CY2017 govx Revenue From Collaboration
RevenueFromCollaboration
95000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
77581
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
75607
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
733711
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
294240
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
532615
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
201170
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
643445
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
615418
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35589911
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
34914963
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67905
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
967667
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57224
CY2017 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
481698
CY2016 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1325582
CY2015 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-15976
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
245300000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
93900000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
90300000
CY2017Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8400
CY2017Q4 us-gaap Assets
Assets
490235
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
454030
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1060348
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1101651
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-141303
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-606318
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-41303
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
312727
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.07
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32751578
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
245852413
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106736810
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55235233
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106736810
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55235233
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
106737
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
55235
CY2017 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
298
CY2016 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
123
CY2015 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
CY2017 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
19862000
CY2016 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1400000
CY2015 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19123959
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28331759
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16273259
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24689298
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
5532
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1331
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
949340
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
892231
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1709867
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2748899
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19123959
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28331759
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
29265
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
33871
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
40296
CY2017Q4 us-gaap Deposits Assets
DepositsAssets
11010
CY2016Q4 us-gaap Deposits Assets
DepositsAssets
11010
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28027
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28780
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28935
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28027
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28780
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28935
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017Q4 us-gaap Grants Receivable
GrantsReceivable
59758
CY2016Q4 us-gaap Grants Receivable
GrantsReceivable
28074
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
441445
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1232368
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2131426
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1429731
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-9406485
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1051279
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
866121
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
10086795
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-737855
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1112378
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-936936
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
436
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
2012
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
2914
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-57109
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-59087
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-67901
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
242857
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-60033
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13314
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5626
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12146
CY2017 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
31684
CY2016 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-91904
CY2015 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
40637
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
4286
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
1666
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
5465
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
151748
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
149288
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
146092
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
490235
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
610217
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
811292
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
369847
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"> </div></div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"><div style="display: inline; font-weight: bold;">Description</div><div style="display: inline; font-weight: bold;"> of Business</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more potential strategic partners.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area). <div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div></div>
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1551511
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1339801
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2679810
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4350
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15850
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1688464
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1946119
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2705263
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-2170162
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-3271701
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-2689287
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4286
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1666
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5465
CY2017 us-gaap Operating Expenses
OperatingExpenses
3249718
CY2016 us-gaap Operating Expenses
OperatingExpenses
4102285
CY2015 us-gaap Operating Expenses
OperatingExpenses
3122833
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-2174448
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-3273367
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-2694752
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
156545
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18476
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4350
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15850
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75589
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
62275
CY2017 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Period to Period Comparisons</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be relied upon as predictive of the results for future periods.<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;</div></div></div></div></div></div></div></div></div>
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
571511
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1339801
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
980000
CY2016 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
2679810
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
674596
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
670246
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31151
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
54828
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2017350
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1970859
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1693102
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-37916790
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35746628
CY2017 us-gaap Revenue From Grants
RevenueFromGrants
1075270
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
828918
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
428081
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.21
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.29
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
57224
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
967667
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
67905
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8973
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8872
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9143
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0226
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0199
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1951484
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.90
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
155200
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
15.25
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3680000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.04
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.05
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.09
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3499475
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7024275
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.05
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y219D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y292D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
58337
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
54757
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
66622
CY2015 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2679810
CY2017 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
980000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1339801
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
571511
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-321057
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
240370
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
1146175
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
1204603
CY2017Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
79000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expense<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">s during the reporting period. Actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>differ from those estimates.</div></div></div></div></div></div></div></div></div>
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68605817
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41516514
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31950813

Files In Submission

Name View Source Status
0001437749-18-005301-index-headers.html Edgar Link pending
0001437749-18-005301-index.html Edgar Link pending
0001437749-18-005301.txt Edgar Link pending
0001437749-18-005301-xbrl.zip Edgar Link pending
a1.jpg Edgar Link pending
a2.jpg Edgar Link pending
ex_107977.htm Edgar Link pending
ex_107978.htm Edgar Link pending
ex_107979.htm Edgar Link pending
ex_107980.htm Edgar Link pending
ex_107981.htm Edgar Link pending
ex_107982.htm Edgar Link pending
ex_107983.htm Edgar Link pending
ex_107985.htm Edgar Link pending
ex_107986.htm Edgar Link pending
ex_107987.htm Edgar Link pending
ex_107988.htm Edgar Link pending
ex_107989.htm Edgar Link pending
ex_108047.htm Edgar Link pending
ex_108048.htm Edgar Link pending
ex_108049.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
govx-20171231.xml Edgar Link completed
govx-20171231.xsd Edgar Link pending
govx-20171231_cal.xml Edgar Link unprocessable
govx-20171231_def.xml Edgar Link unprocessable
govx-20171231_lab.xml Edgar Link unprocessable
govx-20171231_pre.xml Edgar Link unprocessable
govx20171231_10k.htm Edgar Link pending
maxim.jpg Edgar Link pending
mazim_sm.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vlpshot.jpg Edgar Link pending